Takeda Pharmaceutical Co Ltd (TAK)
12.92
-0.06
(-0.50%)
USD |
NYSE |
Jun 26, 16:00
12.92
0.00 (0.00%)
After-Hours: 20:00
Takeda Pharmaceutical Cash from Financing (Quarterly): -450.06M for March 31, 2024
Cash from Financing (Quarterly) Chart
Historical Cash from Financing (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | -450.06M |
| December 31, 2023 | -632.25M |
| September 30, 2023 | -952.69M |
| June 30, 2023 | -421.06M |
| March 31, 2023 | -268.38M |
| December 31, 2022 | -3.046B |
| September 30, 2022 | -272.26M |
| June 30, 2022 | -1.665B |
| March 31, 2022 | -2.263B |
| December 31, 2021 | -1.288B |
| September 30, 2021 | -2.227B |
| June 30, 2021 | -3.755B |
| March 31, 2021 | -3.389B |
| December 31, 2020 | -2.937B |
| September 30, 2020 | -2.149B |
| June 30, 2020 | -1.791B |
| March 31, 2020 | -1.328B |
| December 31, 2019 | -353.41M |
| September 30, 2019 | -5.951B |
| June 30, 2019 | -1.617B |
| March 31, 2019 | 14.05B |
| December 31, 2018 | 13.40B |
| September 30, 2018 | -118.49M |
| June 30, 2018 | -753.32M |
| March 31, 2018 | -1.384B |
| Date | Value |
|---|---|
| December 31, 2017 | -585.80M |
| September 30, 2017 | -184.37M |
| June 30, 2017 | -790.50M |
| March 31, 2017 | 2.393B |
| December 31, 2016 | -670.16M |
| September 30, 2016 | -82.73M |
| June 30, 2016 | 1.041B |
| March 31, 2016 | 300.42M |
| December 31, 2015 | -536.25M |
| September 30, 2015 | -90.84M |
| June 30, 2015 | -713.66M |
| March 31, 2015 | -1.273B |
| December 31, 2014 | -458.27M |
| September 30, 2014 | -245.10M |
| June 30, 2014 | -775.89M |
| March 31, 2014 | -125.25M |
| December 31, 2013 | -662.29M |
| September 30, 2013 | 2.398B |
| June 30, 2013 | -647.36M |
| March 31, 2011 | -44.50M |
| December 31, 2010 | -807.49M |
| September 30, 2010 | -157.47M |
| June 30, 2010 | -692.50M |
| March 31, 2010 | -71.51M |
| December 31, 2009 | -731.82M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (Quarterly) Range, Past 5 Years
-5.951B
Minimum
Sep 2019
-268.38M
Maximum
Mar 2023
-1.838B
Average
-1.641B
Median
Cash from Financing (Quarterly) Benchmarks
| Ovid Therapeutics Inc | 0.228M |
| Astellas Pharma Inc | 306.03M |
| Pfizer Inc | -4.931B |
| Nxera Pharma Co Ltd | -12.29M |
| PeptiDream Inc | -5.103M |
Cash from Financing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | 1.999B |
| Cash from Investing (Quarterly) | -489.35M |
| Free Cash Flow | 1.633B |
| Free Cash Flow Per Share (Quarterly) | 0.4637 |
| Free Cash Flow to Equity (Quarterly) | 2.559B |
| Free Cash Flow to Firm (Quarterly) | 1.506B |
| Free Cash Flow Yield | 4.00% |